Amoneta Diagnostics attends the AD/PD™ 2024 International Conference

We are honored to announce our participation in the forthcoming AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases in Lisbon. As innovators in the pursuit of scientific progress and therapeutic advancements for neurodegenerative disorders, we eagerly anticipate the opportunity to engage with fellow experts and present our latest innovation: the APO-Easy® Genotyping Kit.

Designed to enhance Alzheimer’s disease (AD) diagnosis and patient management, our kit detects specific single nucleotide polymorphisms (SNPs) associated with the APOE gene. This genetic information is pivotal in assessing an individual’s susceptibility to AD, particularly concerning the ε4 allele, a well-established risk factor for late-onset AD.

Our commitment to precision medicine is underscored by the potential of the APO-Easy® Genotyping Kit to inform personalized treatment strategies, including the utilization of emerging disease-modifying therapies such as monoclonal antibodies. As we navigate the CE-marking process, ensuring compliance with rigorous regulatory standards, we anticipate its imminent integration into clinical practice, offering clinicians invaluable insights for informed decision-making.

At AD/PD™ 2024, we look forward to sharing our expertise, exchanging insights, and forging collaborative partnerships to propel the field of neurodegenerative disease projects forward.

Join us in Lisbon as we unite in our collective mission to advance science, improve patient outcomes, and pave the way towards a brighter future for those affected by neurodegenerative disorders.